Author: Bill Ross | Reading Time: 7 minutes | Published: February 24, 2026 | Updated: March 6, 2026 A mid-size contract research organization (CRO) faced declining sponsor inquiries despite strong clinical trial capabilities and a lackluster digital presence. Over nine months, we implemented a strategy that increased qualified sponsor inquiries by 70%. Here, we outline the situation, our approach, key decisions, and results. This CRO had about 200 employees and offices in three U.S. cities. They focused on Phase I-III clinical trials in oncology, immunology, and rare diseases. Their reputation grew through word-of-mouth and conference networking. However, as online competition increased in the pharmaceutical space, these traditional channels were no longer enough to meet their growth goals. This growing gap between offline reputation and online visibility prompted a closer look at their digital strategy. Their website had not been updated in four years. Aside from a few blog posts written by an intern in 2021, there was no real content strategy. The service pages sounded like internal documents instead of persuasive content for sponsors. As a result, when pharmaceutical or biotech sponsors searched online for CRO partners, this organization did not appear in the search results, putting them at a disadvantage as competitors with stronger digital presences emerged. Key metrics at the start of the engagement: The numbers made it clear: this CRO was trying to attract sponsors in a global market expected to reach over $99 billion by 2026, but its online presence was acting more like a digital business card than a real marketing tool. Improvements in the following months directly increased website traffic, raised RFI submissions by over 70%, and lengthened site visit duration. Before we explain our strategy, it helps to understand why so many mid-size CROs run into this problem. Marketing in the life sciences presents unique challenges distinct from those in most other B2B industries, setting the stage for the barriers we addressed in our project. First, the process for choosing a clinical research partner is long and complicated. Pharmaceutical or biotech sponsors do not fill out contact forms on a whim. They spend weeks or even months researching CROs, looking at published expertise, checking for therapeutic specialization, and often start with an RFI before sending a formal Request for Proposal (RFP). If a CRO is not visible during this early research, it will not make the shortlist. Second , mid-size CROs often position themselves with vague value propositions. Phrases like “flexible, full-service partner” and “patient-focused approach” appear on nearly every CRO website. When every organization sounds the same, sponsors cannot distinguish one from another, and they default to recognizable names or to whoever ranks highest in search results.
“Most mid-size CROs deliver outstanding clinical work, but their websites read like internal capability decks. Sponsors are searching for answers to specific problems, and if your content does not address those problems directly, you become invisible during the selection process.” – Strategy Team, Emulent Marketing.
Third, clinical research organizations often do not spend enough on digital marketing. Most of their business development budget goes to conference sponsorships and direct outreach, leaving little for improving search visibility or building content. This means their digital presence does not show the true quality of their work. Common gaps we see in mid-size CRO marketing programs: If your CRO faces similar challenges, consider adopting this structured approach to improve sponsor engagement. This approach allowed us to address foundational issues before moving to content and conversion. We broke the project into three phases, each lasting about three months. Each phase built on the last: Phase 1 focused on foundation and positioning, Phase 2 on content and authority, and Phase 3 on conversion and scaling. Throughout, we asked ourselves one key question: What does a pharmaceutical or biotech sponsor need to see, read, and experience before submitting an RFI? Our first priority was to rebuild the CRO’s website design and structure to better attract sponsors. We began by interviewing three current sponsor contacts and two business development team members to understand how decisions were made from both perspectives. From these conversations, we learned that sponsors look at therapeutic depth, team expertise, regulatory history, and geographic reach when choosing a CRO. However, the existing website did not cover these topics clearly or in an easy-to-find way. Key actions during Phase 1:
“The biggest shift in Phase 1 was moving from ‘here is what we do’ messaging to ‘here is the specific problem we solve for you’ messaging. That one change affected everything, from page titles to call-to-action buttons to the way service descriptions were written.” – Strategy Team, Emulent Marketing.
Once the foundation was set, Phase 2 focused on creating content to attract sponsors while they researched and evaluated CROs. We did not just publish blog posts for the sake of it. Each piece of content answered a specific sponsor question, targeted specific keywords, and aligned with a stage in the buyer journey. We developed what we call a “sponsor decision content map,” which plots the questions sponsors ask at each stage of CRO evaluation against the content types most likely to answer them. We produced 24 pieces of content over three months, ranging from long-form therapeutic area guides (2,500+ words) to shorter FAQ pages addressing common sponsor concerns. Every piece was built on entity-based SEO principles, connecting the CRO’s name and expertise to relevant clinical research entities that search engines associate with sponsor-intent queries. Content categories and their purposes: By month seven, organic traffic was growing, and new visitors were spending more time on the site. But we knew that traffic alone does not fill a sponsor inquiry pipeline. Phase 3 focused on turning that growing audience into qualified RFI submissions. We analyzed user behavior data from the first six months and identified three critical drop-off points in the sponsor journey: service pages with no clear next step, the “About” section where visitors went to evaluate credibility but found thin content, and the RFI form itself, which asked for too much information upfront. Conversion improvements made in Phase 3:
“Sponsors do not convert in one visit. The typical path we tracked was three to five website sessions spread over two to four weeks before an RFI submission. That meant every page had to reinforce credibility and move the visitor one step closer to reaching out.” – Strategy Team, Emulent Marketing.
The results built gradually, which is typical for a pharmaceutical and life sciences SEO engagement where trust, authority, and content depth compound over time. Here are the key metrics that changed from baseline to month nine. The 70% increase in RFI submissions directly translated into a revenue opportunity. Each qualified sponsor inquiry for this CRO ranged from $800,000 to $2.5 million, depending on the trial phase and scope. Adding roughly 2-3 additional qualified inquiries per month significantly expanded their sales pipeline relative to where they started. Beyond the numbers, the business development team reported qualitative improvements. Sponsors who found the CRO through organic search arrived better informed about capabilities and therapeutic focus, which shortened initial conversations and reduced time spent educating prospects on basic qualifications. Not every action we took produced equal results. Looking back at the data, three specific decisions accounted for most of the improvement. The first was building therapeutic-specific landing pages. Before the engagement, a sponsor searching for “oncology CRO Phase II trials” would never find this organization. Afterward, the dedicated oncology page ranked on the first page for 8 related search terms and became the site’s highest-traffic service page. Therapeutic specialization content accounted for 44% of all new organic traffic by month nine. The second was the simplification of the RFI form. Reducing friction at the point of conversion had an outsized impact. The 38% increase in form completion rate, compounded with the traffic gains, led to a 70% increase in inquiries. This reinforced a principle we apply across all of our B2B marketing engagements: making it easy for qualified buyers to take action matters as much as driving them to the page. The third was trust and authority building through E-E-A-T signals. Adding team profiles with published research credits, regulatory approval histories, and specific trial data transformed the CRO’s website from a generic brochure into a credible resource for evaluating partners. This directly reduced bounce rates and increased the number of pages visitors explored before leaving. The shift toward non-branded organic search as the primary source of new inquiries was significant. It meant the CRO was no longer dependent on sponsors who already knew its name. For the first time, they were reaching new pharmaceutical and biotech decision-makers during the active research phase of CRO selection. The global CRO services market is projected to reach nearly $100 billion by 2026, with mid-size and niche CROs continuing to win market share from larger competitors in specialized therapeutic areas. But winning that share requires more than clinical excellence. Sponsors are making shortlist decisions based on what they find online, and the CROs that invest in their content strategy for brand differentiation will have a meaningful advantage. Principles that apply to any mid-size CRO marketing program:
“The CRO market is growing fast, but visibility is not keeping pace for most mid-size organizations. The firms that treat their digital presence as a sponsor acquisition channel, rather than an afterthought, will be the ones that capture the outsourcing growth ahead.” – Strategy Team, Emulent Marketing.
Growing a CRO’s sponsor inquiry pipeline requires more than a new website or a few blog posts. It requires a connected strategy that aligns positioning, content, technical search visibility, and conversion design around how sponsors actually research and select clinical research partners. Our team at Emulent builds these strategies for life sciences and pharmaceutical organizations that need their online presence to generate real business development results. If your CRO or life sciences brand needs help building a digital marketing program that drives qualified sponsor inquiries, contact the Emulent team to start a conversation about what that could look like for your organization. How We Helped a Mid-Size CRO Increase Sponsor Inquiries by 70% in 9 Months
What Was Happening Before We Got Involved?
Why Do Most Mid-Size CROs Struggle With Sponsor Acquisition Online?
With these challenges in mind, we created a three-phase strategy to improve the sponsor inquiry pipeline.
Phase 1 (Months 1-3): Foundation and Positioning
Phase 2 (Months 4-6): Content and Authority Building
Phase 3 (Months 7-9): Conversion Optimization and Scaling
What Were the Specific Results After 9 Months?
Which Tactics Made the Biggest Difference?
What Can Other CROs Learn From This Engagement?
Conclusion
